Few data exist on the impact of non-steroidal anti-inflammatory drug (NSAID) use on peptic ulcer outcome.
Dr Thomsen and colleagues from Denmark examined the 30-day mortality from peptic ulcer bleeding.
The research team also assessed the association of traditional non-steroidal anti-inflammatory drugs and newer selective cyclo-oxygenase-2 inhibitors with mortality.
The team conducted a cohort study of patients with a first hospitalization for peptic ulcer bleeding in 3 Danish counties between 1991 and 2003.
Data on pre-admission non-steroidal anti-inflammatory drug use were obtained from population-based registries.
The team obtained further data on use of other ulcer-related drugs, and comorbidities from population-based registries.
|The adjusted mortality rate ratio for users of rofecoxib was 1.2|
|Alimentary Pharmacology & Therapeutics|
The researchers accessed follow-up data on mortality from the Danish Civil Registry System.
Of 7232 patients hospitalized for peptic ulcer bleeding, 28% were current non-steroidal anti-inflammatory drug users.
The team found that the 30-day mortality was 11% overall, and 13% among current non-steroidal anti-inflammatory drug users.
Compared with never-use, the adjusted 30-day mortality rate ratios were 1.4 for current use of non-steroidal anti-inflammatory drugs alone.
The researchers noted that the adjusted 30-day mortality rate ratio for current use combined with other ulcer-related drugs was 1.3.
For users of celecoxib, alone and in combination, adjusted mortality rate ratios were 1.4 and 2, respectively.
The team noted that for users of rofecoxib and in combination, the adjusted mortality rate ratio was 1.2 and 0.9, respectively.
Dr Thomsen's team concludes, “Among patients hospitalized with peptic ulcer bleeding, use of non-steroidal anti-inflammatory drugs, including some newer cyclo-oxygenase-2 inhibitors, is associated with increased short-term mortality.”